Day: June 28, 2022

iTolerance, Inc. Awarded Industry Discovery and Development Partnership with JDRF for Advanced Pre-Clinical Development of iTOL-100 and iTOL-101 for the Treatment of Type 1 Diabetes

Company advancing development of lead program, iTOL-101, as a potential breakthrough in curing Type 1 Diabetes with the potential to...

Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium

Research was performed by scientists at George Mason University's Center for Infectious Disease Research (formerly NCBID)WAKEFIELD, MA / ACCESSWIRE /...

error: Content is protected !!